Welcome to our dedicated page for Baird Medical Investment Holdings Ordinary Share news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical Investment Holdings Ordinary Share stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Baird Medical Investment Holdings Ordinary Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Baird Medical Investment Holdings Ordinary Share's position in the market.
Baird Medical (NASDAQ: BDMD) sponsored and participated in the 2024 Guangdong Thyroid Surgery Committee Annual Meeting in Guangdong, China. The two-day event, hosted by the Guangdong Provincial Hospital of Traditional Chinese Medicine, focused on advancing thyroid disease treatment. Baird Medical showcased its microwave ablation (MWA) technology and engaged with healthcare professionals to discuss innovations in endoscopic and minimally invasive surgery.
Chairwoman Haimei Wu emphasized the meeting's importance as a platform for sharing advancements in thyroid ablation and fostering collaboration among experts. The company utilized the interactive sessions to engage with specialists about current challenges and future directions in thyroid care, reinforcing its commitment to advancing minimally invasive surgery solutions globally.
Baird Medical (NASDAQ: BDMD) recently sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid care advancement. Led by Dr. Emad Kandil from Tulane University School of Medicine, the program provided hands-on training to two endocrinologists who observed seven live MWA cases.
Dr. Kandil, who has performed over 80 MWA procedures, recently presented at the American Thyroid Association meeting, highlighting MWA's effectiveness compared to Radiofrequency Ablation. The participating physicians received Certificates of Completion, preparing them to integrate MWA into their clinical practices.
The initiative reflects Baird Medical's commitment to expanding access to minimally invasive therapies through physician education and training partnerships.
Baird Medical Group (NASDAQ: BDMD) held its 2024 Annual Review and 2025 Planning Meeting at Baird Capital Tower in Guangzhou, China. The two-day event included participation in the 7th Thyroid Disease Forum and comprehensive reviews of market performance and future strategies.
Production Manager Le Zhang presented the 2025 production schedule and plans for enhanced after-sales service. The company's leadership discussed strengthening distributor relationships to support global expansion goals. The meeting highlighted Baird Medical's recent NASDAQ listing as a milestone that increased international recognition in the minimally invasive medical technologies sector.
Baird Medical (NASDAQ: BDMD) sponsored and participated in the 2024 7th Thyroid Disease Standardized Diagnosis and Treatment Forum in Guangzhou, China. The company showcased its advanced microwave ablation (MWA) technology for thyroid treatments, which features larger ablation zones and shorter treatment times. The event, hosted by Guangdong Provincial People's Hospital, brought together leading medical experts to discuss standardized treatment protocols for thyroid diseases. Chairwoman Haimei Wu emphasized the company's commitment to advancing solutions for thyroid disease management and improving patient outcomes globally.
Baird Medical (NASDAQ: BDMD) sponsored the Surgery of the Thyroid and Parathyroid Glands Course at Massachusetts General Hospital. The event featured discussions on thyroid and parathyroid surgery advancements, with Dr. Shuhang Xu presenting on microwave ablation (MWA) technology for treating thyroid conditions. The presentation highlighted MWA's benefits, including minimally invasive approach, shorter procedures, and precise ablation capabilities. The course covered upcoming American Thyroid Association guidelines and innovations in thyroid cancer management.
Baird Medical (NASDAQ: BDMD) showcased its microwave ablation technology at the Massachusetts Society of Otolaryngology (MSO) event, highlighting its benefits for minimally invasive, office-based surgical procedures. The technology promises higher precision, reduced procedure time, and improved patient recovery, aligning with current trends in Otolaryngology. Attendees showed strong interest in the technology's potential to enhance patient care outcomes and practice efficiency. Baird Medical reaffirmed its commitment to supporting the Otolaryngology community with advanced tools.
Baird Medical (BDMD) showcased its microwave ablation (MWA) technology at the 2024 American Thyroid Association Annual Meeting, drawing significant international attention. The event featured presentations by notable experts, including Dr. Emad Kandil from Tulane University and Dr. Feng Han from Sun Yat-sen University Cancer Center. Dr. Kandil presented clinical data demonstrating MWA's success in cases where RFA failed, emphasizing its safety and effectiveness for thyroid nodule treatment. Dr. Han shared insights on advanced procedural techniques and energy management based on his extensive experience with MWA procedures. The event concluded with hands-on demonstrations of Baird's technology.
Baird Medical hosted and participated in several key thyroid health events from October 24-27, 2024, fostering international collaboration between U.S. and Chinese experts. The company organized the Sixth Global Thyroid Microwave Ablation Technology Exchange Conference on October 25, focusing on advancements in microwave ablation for benign thyroid nodules. Additionally, Baird participated in the 9th Annual China Thyroid Association Conference, the inaugural Western Thyroid Diagnosis and Endoscopy Training Session, and the 4th Hunan Thyroid and Breast Health Forum, demonstrating its commitment to advancing global thyroid care standards.
Baird Medical (NASDAQ: BDMD) participated in the 2024 American College of Surgeons Clinical Congress in San Francisco, showcasing its microwave ablation (MWA) technology to over 10,000 attendees, including 7,000 surgeons. At Booth 1061, the company demonstrated MWA applications for thyroid nodules, breast disease, liver cancer, and uterine fibroids. The technology, already adopted by institutions like Columbia University and Weill Cornell, attracted significant interest through hands-on simulations. Baird participated in panel discussions on ablative therapies and engaged with endocrine surgery leaders, reinforcing its commitment to market expansion.
Baird Medical Investment Holdings (NASDAQ: BDMD), a leading developer of microwave ablation (MWA) medical devices, announced its participation in the American Thyroid Association (ATA) Annual Meeting from October 30 to November 3, 2024, in Chicago. The company will showcase its innovations at Booth 100 and host an Expo Theater Presentation on November 2, titled 'Latest Advancements in MWA for Thyroid Treatment'.
The presentation will feature experts from Tulane University, Sun Yat-sen University, and Houston Methodist Hospital. Baird Medical's participation highlights its expansion into the U.S. market following FDA clearance for its MWA technology, offering a minimally invasive alternative to thyroidectomy for benign thyroid tumors. With over 150,000 thyroidectomies performed annually in the U.S., Baird Medical's technology presents a safer option for patients.
FAQ
What is the current stock price of Baird Medical Investment Holdings Ordinary Share (BDMD)?
What is the market cap of Baird Medical Investment Holdings Ordinary Share (BDMD)?
